Perspective Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Mar 16, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 16, 2026
CATX$0.79-8.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
Consolidated Statements of Cash Flows
(In thousands, except shares)
| Year Ended December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| CASH FLOWS FROM OPERATING ACTIVITIES: | ||
| Net loss | $(103,121) | $(79,279) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Foreign currency adjustments | 250 | (65) |
| Depreciation expense and amortization | 3,251 | 2,306 |
| Loss on disposal of property and equipment | - | 27 |
| Net accretion of discounts on available-for-sale securities | (2,723) | (607) |
| Loss on divestiture | - | 59 |
| Goodwill impairment | - | 24,062 |
| In-process research and development impairment | 10,000 | - |
| Share-based compensation | 8,966 | 5,387 |
| Deferred income tax benefit | (793) | (2,097) |
| Other, net | 5 | 99 |
| Changes in operating assets and liabilities: | ||
| Accounts receivable | 110 | 1,049 |
| Inventory related to discontinued operations (Note 4) | - | 11 |
| Interest receivable | (142) | (880) |
| Prepaid expenses and other current assets | 624 | (1,911) |
| Accounts payable and accrued expenses | 147 | 1,890 |
| Deferred Income1 | (1,400) | 28,000 |
| Accrued personnel expenses | 2,011 | 3,600 |
| Other noncurrent liabilities | 331 | 55 |
| Net cash used in operating activities | (82,484) | (18,294) |
| CASH FLOWS FROM INVESTING ACTIVITIES: | ||
| Additions to property and equipment | (12,749) | (54,414) |
| Proceeds from the sale of property and equipment | - | 335 |
| Additions to other assets | (135) | (72) |
| Maturities of available-for-sale securities | 173,950 | - |
| Purchases of available-for-sale securities | (119,838) | (164,780) |
| Proceeds from maturity of held-to-maturity investments | - | 78,730 |
| Purchases of held-to-maturity investments | - | (78,730) |
| Net cash provided by (used in) investing activities | 41,228 | (218,931) |
| CASH FLOWS FROM FINANCING ACTIVITIES: | ||
| Repayment of notes payable | (52) | (48) |
| Proceeds from sales of common stock, pursuant to exercise of warrants, net | - | 125 |
| Proceeds from sales of common stock, pursuant to exercise of options | 371 | 1,253 |
| Proceeds from the sales of common stock and Pre-funded Warrants, net1 | - | 288,055 |
| Proceeds from the issuance of common stock pursuant to the ATM, net1 | 9,986 | - |
| Net cash provided by financing activities | 10,305 | 289,385 |
| Net (decrease) increase in cash and cash equivalents | (30,951) | 52,160 |
| Cash and cash equivalents at beginning of period | 61,580 | 9,420 |
| CASH AND CASH EQUIVALENTS AT END OF PERIOD | $30,629 | $61,580 |
| Supplemental schedule of noncash investing and financing activities: | |||
|---|---|---|---|
| Property and equipment in accounts payable and accrued expenses | $9,771 | $ | - |
| Recognition of operating lease liability and right-of-use asset | 205 | 2,115 | |
See Note 3, Investments and Agreements, for additional information.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.